Transcode Therapeutics, Inc.

RNAZ Nasdaq SEC CIK 1829635
Follow Transcode Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$107.4M −2111.3% vs same quarter last year
EPS, diluted −$9.36 −60.8% vs same quarter last year
Operating cash flow −$7.7M −87.7% vs same quarter last year
Operating income −$109.7M −2304.8% vs same quarter last year
Net income by quarter
−$5.9M
−$12.1M
−$4.3M
−$4.9M
−$13.4M
−$17.8M
−$6.8M
−$107.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$34.7M
FY24−$16.8M
FY23−$18.5M
FY22−$17.6M
FY21−$6.8M
FY20−$2.3M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$19.5M
FY24−$13.4M
FY23−$18.1M
FY22−$15.9M
FY21−$5.5M
FY20-
FY19-